Advances in microfabrication allow for highly sensitive calorimeters with dramatically reduced volume, decreased response time and increased energy resolution. These calorimeters hold the potential for designs of ELISA platforms competitive with fluorescent and chemiluminescent technologies. We have developed a new assay platform using conventional ELISA reagents to produce a thermal signal quantifiable using calorimetry. Our optimized micromachined calorimeters have nL reaction volumes and a minimum detectable power of 375 pW/Hz^1/2. We demonstrate rapid quantification in a model system of trastuzumab, a humanized monoclonal antibody used in the treatment of HER2 overexpressing breast cancers, in human serum using a HER2 peptide mimetic. Trastuzumab concentration and reaction time constant correlated well (R² = 0.954) and can be used to determine trastuzumab concentrations. The limit of detection for the ThermometricELISA (TELISA) was 10 μg/ml trastuzumab in human serum. TELISA allows for a simple readout, reduction in assay time, sample and reagent volumes and has the potential to become a point of care multiplexed platform technology.

中文翻译：

---

微型量热计，用于在一纳升的液滴中进行酶联免疫吸附测定。

微细加工的发展使得高灵敏的量热仪体积大大减小，响应时间缩短，能量分辨率提高。这些量热仪具有与荧光和化学发光技术竞争的ELISA平台设计潜力。我们已经开发了一种使用常规ELISA试剂的新测定平台，以产生可通过量热法定量的热信号。我们优化的微机械量热仪具有nL反应体积和375 pW / Hz ^1/2的最小可检测功率。我们证明了曲妥珠单抗的模型系统中的快速定量，曲妥珠单抗是一种在人血清中使用HER2肽模拟物用于治疗HER2过表达的乳腺癌的人源化单克隆抗体。曲妥珠单抗浓度与反应时间常数相关性很好（R ²  = 0.954），可用于确定曲妥珠单抗的浓度。在人血清中，ThermometricELISA（TELISA）的检测限为曲妥珠单抗10μg/ ml。TELISA可实现简单的读数，减少测定时间，减少样品和试剂的体积，并有可能成为护理点多重平台技术。